Chondroitin sulfate - IBSA

Drug Profile

Chondroitin sulfate - IBSA

Alternative Names: Chondroitin 4-sulfate - IBSA; Chondroitin 4-sulfate sodium - IBSA; Chondroitin 6-sulfate - IBSA; Chondroitin 6-sulfate sodium - IBSA; Chondroitin sulfate A - IBSA; Chondroitin sulfate A sodium - IBSA; Chondroitin sulfate sodium - IBSA; Chondroitin sulphate - IBSA; Chondrosulf; Condrosulf (IBSA); Condrosulf (Salus Braumapharm)

Latest Information Update: 28 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IBSA
  • Developer IBSA; Laboratoires Genevrier; Sanova Pharma; SPA
  • Class Anti-inflammatories; Antirheumatics; Glycosaminoglycans
  • Mechanism of Action Collagen stimulants; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 13 Jun 2016 Efficacy data from the phase III CONCEPT trial released by IBSA
  • 14 Apr 2014 Phase-III clinical trials in Osteoarthritis in Belgium (PO) (EudraCT2013-001619-62)
  • 14 Apr 2014 Phase-III clinical trials in Osteoarthritis in Poland (PO) (EudraCT2013-001619-62)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top